Latest MEI Pharma Inc. Stories
Live Webcast from New York on Tuesday, April 30 SAN DIEGO, April 23, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Needham Healthcare Conference on Tuesday, April 30, 2013 at 2:20 p.m. Eastern time from the Westin Grand Central Hotel in New York City. A live webcast of the presentation can...
New Pre-Clinical Data Presented at AACR Annual Meeting in Washington, DC SAN DIEGO, April 10, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced the presentation of new data showing the ability of its mitochondrial inhibitor drug candidate, ME-344, to decrease tumor burden and delay recurrence in a pre-clinical in vivo model of recurrent epithelial ovarian cancer, the most lethal of...
SAN DIEGO, April 5, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today an underwritten registered offering of 2,030,000 shares of its common stock at a price per share of $7.50. The offering is expected to settle and close on April 10, 2013, subject to the satisfaction of customary closing conditions. (Logo: http://photos.prnewswire.com/prnh/20120628/LA32362LOGO) The Company...
Live Webcast from San Francisco on Tuesday, March 26 SAN DIEGO, March 20, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, will host its Annual Meeting of Stockholders at 10:00 a.m. Pacific time on Tuesday, March 26, 2013 at the offices of Morgan, Lewis & Bockius LLP, located at One Market, Spear Street Tower in San Francisco, to consider and vote on certain matters, including the election...
Live Webcast from Dana Point on Tuesday, March 19 SAN DIEGO, March 12, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the 25(th) Annual ROTH Conference on Tuesday, March 19, 2013 at 9:00 a.m. Pacific time from the Ritz-Carlton, Laguna Niguel in Dana Point, California. A live webcast of the...
Live Webcast from Boston on Wednesday, March 6 SAN DIEGO, Feb. 27, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present an update on MEI Pharma and its lead oncology drug candidates, Pracinostat, ME-143 and ME-344, at the Cowen and Company 33(rd) Annual Health Care Conference on Wednesday, March 6, 2013...
SAN DIEGO, Feb. 11, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today the appointment of Thomas C. Reynolds, M.D., Ph.D., to its Board of Directors. A biotechnology industry veteran, Dr. Reynolds joins the Board with more than 20 years of oncology drug development experience, including direct oversight in the development and approval of the hematologic cancer drug ADCETRIS(®)....
SAN DIEGO, Jan. 30, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Professor Bryan R.G. Williams, Ph.D., will not stand for re-election to MEI Pharma's Board of Directors upon the expiration of his term at the Company's next Annual Meeting of Stockholders. Professor Williams has been a member of the Board since March 2006 and has served as Chairman since November 2006....
SAN DIEGO, Dec. 19, 2012 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has completed its previously announced private placement of common stock and warrants in a financing led by new investors Vivo Ventures and New Leaf Venture Partners. Gross proceeds from the private placement were $27.5 million, before deducting fees and expenses. The Company intends to use the net...
SAN DIEGO, Nov. 6, 2012 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that preliminary data from a pilot Phase II clinical trial of the Company's investigational oral histone deacetylase (HDAC) inhibitor, Pracinostat, in combination with azacitidine in patients with advanced myelodysplastic syndrome (MDS) has been accepted for poster presentation at the American Society of...
